SPARFLOXACIN FOR THE TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA - A POOLED DATA-ANALYSIS OF 2 STUDIES

A pooled data analysis of two double-blind studies encompassing 1137 e pisodes of community-acquired pneumonia in hospitalised adults, of whi ch 560 were treated with sparfloxacin and 577 were randomised to compa rator antibacterial agents (amoxycillin/clavulanic acid, erythromycin or amoxycillin administered at reference dosages), was performed. The global efficacy rate at the end of treatment in evaluable patients tre ated with sparfloxacin was 88.3% compared with 84.1% in those who rece ived comparator antibacterial agents. This analysis verified the effic acy of this new aminofluoroquinolone, given orally once daily, in the treatment of community acquired pneumonia. The overall outcome favoure d sparfloxacin for use in the empirical treatment of community-acquire d pneumonia.